Hypomelanotic Disorder Clinical Trials

Find Hypomelanotic Disorder Clinical Trials Near You

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Adolescent and Adult Subjects With Non-segmental Vitiligo

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This is a randomized, double-blind, multicenter, placebo-controlled clinical study intended to evaluate the efficacy, safety and population pharmacokinetic profiles of MH004 ointment in eligible participants with NSV.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 75
Healthy Volunteers: f
View:

• Subjects aged 12 to 75 years inclusive at the time of signing the Informed Consent Form (ICF), with no restriction on gender.

• Clinically diagnosed with non-segmental vitiligo.

• Prior to study drug administration, participants with vitiligo shall meet the following criteria regarding vitiligo lesion area: Facial lesion area ≥ 0.3% body surface area (BSA), and Facial Vitiligo Area Scoring Index (F-VASI) score ≥ 0.3.

• Agree to discontinue all vitiligo therapeutic medications and interventions from the time of ICF signature until the end of the last study visit. Over-the-counter (OTC) drugs shall not exert therapeutic effects on vitiligo or interfere with skin pigmentation, including corticosteroids and other immunomodulators. Final eligibility of such OTC drugs shall be determined by the Investigator. Camouflaging makeup is permitted.

• Women of Childbearing Potential (WOCBP) and male participants whose partners are WOCBP must agree to use reliable contraceptive methods throughout the trial period and for 28 days after the last study drug administration (abstinence, prior sterilization, oral contraceptives, and/or barrier methods \[condoms, diaphragms, cervical caps, etc.\]). For WOCBP, the human chorionic gonadotropin (hCG) pregnancy test result at the screening visit and prior to the first drug administration at the baseline visit must be negative. Male participants shall not donate sperm during the trial and for 3 months after study completion or drug discontinuation.

• The participant and/or their legal guardian shall fully understand the trial content, requirements and procedures, voluntarily participate in this clinical trial and sign the ICF, and be willing and able to comply with scheduled visits, treatment regimens, laboratory tests and other study procedures throughout the trial.

Locations
Other Locations
China
Peking University People's Hospital
RECRUITING
Beijing
Contact Information
Primary
CMO/ Senior Vice President of R&D
jwshi@minghuipharma.com
+ 86 0571-86963293
Time Frame
Start Date: 2026-08-04
Estimated Completion Date: 2028-10-04
Participants
Target number of participants: 405
Treatments
Experimental: Double-Masked Period: MH004 1.0% Ointment
Participants received MH004 1.0% Ointment topically twice a day (BID) from Day 1 to Week 24 during the Double-Masked Period.
Placebo_comparator: Double-Masked Period: MH004 Placebo
Participants received MH004 Placebo Ointment topically twice a day (BID) from Day 1 to Week 24 during the Double-Masked Period.
Experimental: Extended Treatment Period: MH004 1.0% Ointment
Participants received MH004 1.0%Ointment twice a day (BID) from Week 25 to Week 52 during the Extended Treatment Period.
Related Therapeutic Areas
Sponsors
Leads: Minghui Pharmaceutical (Hangzhou) Ltd

This content was sourced from clinicaltrials.gov